SIGY OTC
Sigyn Therapeutics, Inc.
1W: -6.1%
1M: +13.3%
3M: -17.8%
YTD: -98.1%
1Y: -99.1%
3Y: -87.8%
5Y: -95.8%
$0.03
-0.00 (-6.35%)
Weekly Expected Move ±34.4%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$6K
+36.6% ▲
Operating Income
-$3M
-2.6% ▼
Net Income
-$3M
+19.4% ▲
EPS (Diluted)
$-2.51
+33.4% ▲
EBITDA
-$3M
-3.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -100.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $11K | $536 | $10K | $9K | $6K |
| Gross Profit | -$11K | -$536 | -$10K | -$9K | -$6K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $27K | $734K | $658K | $798K | $773K |
| SG&A Expenses | $889K | $1M | $1M | $2M | $2M |
| Operating Expenses | $916K | $2M | $2M | $2M | $3M |
| Operating Income | -$916K | -$2M | -$2M | -$2M | -$3M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $343K | $399K | $647K | $2M | $860K |
| Income Before Tax | -$1M | -$3M | -$3M | -$4M | -$3M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$3M | -$4M | -$4M | -$3M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.22 | $-0.09 | $-3.97 | $-3.77 | $-2.51 |
| EBITDA | -$905K | -$3M | -$2M | -$2M | -$3M |
| Shares Outstanding | 7M | 36M | 934000 | 1M | 1M |